AZD8853

Clinically, GDF15 has shown potential as a biomarker, offering diagnostic precision and prognostic value, particularly when combined with established markers such as prostate-specific antigen. The review concludes with a discussion on several monoclonal antibodies targeting GDF15 in clinical trials, such as AV-380, NGM120, Visugromab, and AZD8853, highlighting promising strategies for novel therapies and precision medicine.

AZD8853 was well tolerated; however, no objective responses or pharmacodynamic effects were seen and GDF15 suppression was not sustained. The study was stopped after dose escalation.

P1/2, N=16, Terminated, AstraZeneca | N=165 --> 16 | Trial completion date: Jun 2024 --> Jun 2023 | Recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Jun 2023; This study was terminated in accordance to protocol Section 4.4, based on the overall risk-benefit profile observed to date.

Abstract is embargoed at this time.

P1/2, N=165, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

P1/2, N=165, Not yet recruiting, AstraZeneca

Depletion of T cells, using anti-CD4 and anti-CD8, in mice ablates the anti-tumor activity observed with anti-GDF15 mAb treatment. These results suggest that inhibition of GDF15 by AZD8853 may be an attractive therapeutic strategy for patients with solid tumors that have high expression of GDF15.